# Infinity Pharmaceuticals, Inc. clinical trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Infinity Pharmaceuticals, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Infinity Pharmaceuticals, Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/infinity-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 10, 2019 | NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | Infinity Pharmaceuticals, Inc. | Phase 2 | Completed | Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03980041) |
| May 23, 2019 | NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | Infinity Pharmaceuticals, Inc. | Phase 2 | Unknown | Breast Cancer, Renal Cell Carcinoma | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03961698) |
| December 22, 2015 | NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Infinity Pharmaceuticals, Inc. | Phase 1 | Unknown | Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02637531) |
| May 31, 2012 | NCT01609179 | IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 | Infinity Pharmaceuticals, Inc. | Not applicable | Completed | Basal Cell Carcinoma, Chondrosarcoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01609179) |
| September 2, 2011 | NCT01427946 | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | Infinity Pharmaceuticals, Inc. | Phase 1/2 | Completed | Non-small Cell Lung Cancer | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01427946) |
| June 13, 2011 | NCT01371617 | A Phase 2 Study With IPI-926 in Patients With Myelofibrosis | Infinity Pharmaceuticals, Inc. | Phase 2 | Completed | Primary Myelofibrosis, Fibrosis, Bone Marrow | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01371617) |
| May 30, 2011 | NCT01362400 | A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer | Infinity Pharmaceuticals, Inc. | Phase 2 | Completed | Non Small Cell Lung Cancer | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01362400) |
| March 9, 2011 | NCT01310816 | A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma | Infinity Pharmaceuticals, Inc. | Phase 2 | Completed | Conventional Chondrosarcoma | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01310816) |
| September 2, 2010 | NCT01193491 | Dose Escalation of IPI-493 in Hematologic Malignancies | Infinity Pharmaceuticals, Inc. | Phase 1 | Terminated | Hematologic Malignancies | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01193491) |
| May 25, 2010 | NCT01130142 | A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer | Infinity Pharmaceuticals, Inc. | Phase 1/2 | Completed | Metastatic Pancreatic Cancer | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01130142) |
| September 2, 2009 | NCT00969917 | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma | Infinity Pharmaceuticals, Inc. | Phase 2 | Withdrawn | Dedifferentiated Liposarcoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00969917) |
| January 6, 2009 | NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | Infinity Pharmaceuticals, Inc. | Phase 2 | Terminated | Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00817362) |
| September 29, 2008 | NCT00761696 | A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies | Infinity Pharmaceuticals, Inc. | Phase 1 | Completed | Neoplasms | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00761696) |
| July 29, 2008 | NCT00724425 | A Phase 1 Dose Escalation Study of IPI-493 | Infinity Pharmaceuticals, Inc. | Phase 1 | Terminated | Advanced Malignancies | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00724425) |
| June 3, 2008 | NCT00688766 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | Infinity Pharmaceuticals, Inc. | Phase 3 | Terminated | Gastrointestinal Stromal Tumors | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00688766) |
| March 3, 2008 | NCT00627419 | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma | Infinity Pharmaceuticals, Inc. | Phase 2 | Terminated | Metastatic Melanoma | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00627419) |
| February 5, 2008 | NCT00606814 | Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors | Infinity Pharmaceuticals, Inc. | Phase 1 | Completed | Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00606814) |
| November 29, 2007 | NCT00564928 | A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | Infinity Pharmaceuticals, Inc. | Phase 2 | Completed | Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00564928) |
| February 2, 2007 | NCT00431015 | Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) | Infinity Pharmaceuticals, Inc. | Phase 1/2 | Completed | Lung Cancer | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00431015) |
| January 13, 2006 | NCT00276302 | Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) | Infinity Pharmaceuticals, Inc. | Phase 1 | Completed | Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00276302) |
| June 7, 2005 | NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma | Infinity Pharmaceuticals, Inc. | Phase 1 | Completed | Multiple Myeloma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00113204) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 3 |
| Phase 2 | 9 |
| Phase 3 | 1 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Terminated | 5 |
| Unknown | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Breast Neoplasms | 2 |
| Neoplasms | 2 |
| Gastrointestinal Stromal Tumors | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Melanoma | 2 |
| Hematologic Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Bone Neoplasms | 1 |
| Primary Myelofibrosis | 1 |
| Carcinoma, Renal Cell | 1 |
| Carcinoma, Basal Cell | 1 |
| Chondrosarcoma | 1 |
| Urinary Bladder Neoplasms | 1 |
| Carcinoma, Transitional Cell | 1 |
| Adrenocortical Carcinoma | 1 |
| Mesothelioma | 1 |
| Liposarcoma | 1 |
| Prostatic Neoplasms | 1 |
| Carcinoma, Large Cell | 1 |
| Carcinoma, Squamous Cell | 1 |
| Sarcoma | 1 |
| Pancreatic Neoplasms | 1 |
| Multiple Myeloma | 1 |
| Recurrence | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [EMS training centers in the United States](https://specstream.ai/data/businesses/ems-training-centers/united-states)
- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [Driving schools in the United States](https://specstream.ai/data/businesses/driving-schools/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
